ID   Hs 633.T
AC   CVCL_0832
AS   CVCL_0129
SY   Hs-633-T; Hs 633T; HS 633T; HS-633T; Hs633T; MBA/8387; MB 8387; 8387; Line 8387; HS 8387
DR   CLO; CLO_0004034
DR   MCCL; MCC:0000021
DR   CLDB; cl1718
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7395
DR   cancercelllines; CVCL_0832
DR   Cell_Model_Passport; SIDM00667
DR   Cosmic; 1995445
DR   Cosmic; 2009543
DR   Cosmic-CLP; 1240149
DR   DepMap; ACH-002246
DR   ECACC; 89050201
DR   EGA; EGAS00001000978
DR   GDSC; 1240149
DR   GEO; GSM827368
DR   GEO; GSM1669896
DR   LINCS_LDP; LCL-1436
DR   PharmacoDB; Hs633T_615_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0832
DR   Wikidata; Q54895847
RX   PubMed=375235;
RX   PubMed=833871;
RX   PubMed=1385192;
RX   PubMed=2902939;
RX   PubMed=3518877;
RX   PubMed=5431618;
RX   PubMed=6500159;
RX   PubMed=6935474;
RX   PubMed=6954533;
RX   PubMed=8188761;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Pro (c.436G>C); ClinVar=VCV000375963; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Argfs*60 (c.852delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CRL-7395; true.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 8,11
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 15,20
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   25Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m;
RA   Fleming T.P., Matsui T., Aaronson S.A.;
RT   "Platelet-derived growth factor (PDGF) receptor activation in cell
RT   transformation and human malignancy.";
RL   Exp. Gerontol. 27:523-532(1992).
//
RX   PubMed=2902939; DOI=10.1093/carcin/9.11.2073;
RA   McCormick J.J., Yang D.-J., Maher V.M., Farber R.A., Neuman W.,
RA   Peterson W.D. Jr., Pollack M.S.;
RT   "The HuT series of 'carcinogen-transformed' human fibroblast cell
RT   lines are derived from the human fibrosarcoma cell line 8387.";
RL   Carcinogenesis 9:2073-2079(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=5431618; DOI=10.1016/0014-4827(70)90250-8;
RA   Aaronson S.A., Todaro G.J., Freeman A.E.;
RT   "Human sarcoma cells in culture. Identification by colony-forming
RT   ability on monolayers of normal cells.";
RL   Exp. Cell Res. 61:1-5(1970).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=8188761; DOI=10.1002/jcp.1041590307;
RA   Cuadrado A., Issing W., Fleming T.P., Molloy C.J.;
RT   "Uneven distribution of protein kinase C-alpha and -beta isozymes in
RT   human sarcomas and carcinomas.";
RL   J. Cell. Physiol. 159:434-440(1994).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//